Cancer is the second leading cause of death in the United States and is projected to be the leading cause of death worldwide
this year. There is a critical need for therapeutic approaches that can enhance patients? immune responses to target solid
tumors and their metastases. OpSaniTx is developing an innovative therapeutic vaccine approach that addresses these challenges.
The company has developed the first generation of a proprietary protein, the Opsonokine?, which can significantly enhance
the immune response to a cell based vaccine. The Opsonokine?, a recombinant protein, expressed and purified from yeast, is a
chimeric protein with two independently functioning domains. The first domain is a powerful cytokine, GM-CSF. The second
domain binds to sialic acid residues on the surface of tumor cells. Mixing the protein with tumor cells ex vivo results in the
spontaneous binding of thousands of Opsonokine molecules to each individual cell. When introduced into the patient as a series
of vaccinations, the cytokine coated tumor cells are rapidly taken up by antigen presenting cells, stimulating a strong anti-tumor
Young managed both the scientific and manufacturing Operations at Genitrix LLC and has served as Vice President of OmniGene DX and Director/
Interim Vice President at Cambridge Biotech (acquired by Antigenics). He has also held scientific positions at Integrated Genetics (acquired by
Genzyme) and Abbott Laboratories. Dr Young did his Post-doctoral work at Harvard Medical School after receiving his PH.D.and MA in Molecular
Biology at Indiana University and his BA at the University of Rochester. He holds several patents in molecular biology and vaccine development.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals